Message

Transforming the potential of extracellular vesicle (EV) technology into real-world therapies.

Thank you for visiting the website of EXORPHIA Inc.

We are driven by a strong mission to realize the vast therapeutic potential of extracellular vesicles (EVs) and deliver it to the patients who need it as quickly as possible.

EXORPHIA is now at a more exciting stage than ever before. We are charting a steady growth strategy, driven by two powerful EV platform technologies. One is our "Natural-type EV Platform," which maximizes cells' inherent healing power. The other is our "Engineered EV Platform," which dramatically enhances therapeutic effects by equipping EVs with specific functions.

Under this Dual-Platform Strategy, we are pursuing a clear business plan. First, to build our short-term revenue base, we aim for the early market launch of our additive (EXP02), which helps improve the success rate of in vitro fertilization (IVF). The revenue generated from this will fuel robust investment into the development of large-scale pharmaceuticals with the potential for significant long-term value creation: our anti-inflammatory drug (EXP01) for lung disorders and atopic dermatitis, and our EV vaccine (EXP03), which will lead the next generation of infectious disease prevention.

This strategy allows for sustainable growth while mitigating the development risks that bio-ventures often face. We aim for the success of individual products and are working to build a drug discovery engine where new value is continuously created from our core technologies.

Our endeavors are supported by the passion and expertise of our shareholders, our academic and corporate partners in joint research, and above all, every member of the EXORPHIA team who is passionately dedicated to our daily R&D efforts.

As a leading company in EV technology, EXORPHIA promises to continue pursuing sincere, science-based business development. We pledge to do our utmost to bring hope to couples wishing for children and to deliver new options to patients suffering from intractable diseases.

Together, we will create the future of medicine. We sincerely ask for your continued support and look forward to meeting your expectations.

June 2025
Koji Kuchishi
Founder, President & CEO
EXORPHIA Inc.

Business Model

Our company is engaged in two business areas: the "Drug Discovery Business," which aims to commercialize exosomes as pharmaceuticals, and the "Non-Drug Discovery Business," which sells exosomes as raw materials for non-medical products.

The "Drug Discovery Business" consists of two business models: the "Asset Model," where we conduct clinical trials of our assets, and the "Platform Model," where we license our exosome technology.

Among these, the "Asset Model" is the driver of our medium- to long-term growth. Although research and development investments precede revenue, we aim to increase the value of our assets by obtaining evidence of safety and efficacy in clinical trials targeting diseases with high unmet medical needs. By licensing global rights to pharmaceutical companies, we expect to generate significant revenue.

On the other hand, while the future revenue scale of the "Platform Model" and "Non-Drug Discovery Business" is limited compared to the "Asset Model," they enable us to acquire stable cash flow early with less research and development investment, which is expected to contribute to the improvement of our financial health.

By adjusting the weight of these multiple business models according to our growth stage, we aim to achieve continuous growth over the medium to long term while controlling risks.

Company Profile

Company Name

EXORPHIA, INC.

Business Description

R&D, manufacturing, and sales of exosome-based therapeutics derived from human cells.

Location

Head Office and Lab: Inspired.Lab, 6th Floor, Otemachi Building, 1-6-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

Establishment Date

May 7, 2019

Capital

100 million yen (Accumulated Funds Raised 1,489 million yen)

CEO

Koji Kuchiishi

Academic Research Partners

　　　　

Collaborative Research Representatives

• Professor Ken J. Ishii, M.D., Ph.D., Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo
• Professor KAGE Hidenori, M.D., Ph.D., Department of Respiratory Medicine, The University of Tokyo Hospital
• Associate Professor NAGAMURA-INOUE Tokiko, M.D., Ph.D., Department of Cell Processing and Transfusion, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo
• Associate Professor KOJIMA Ryosuke, Ph.D., Laboratory of Chemical Biology and Molecular Imaging, Graduate School of Medicine, The University of Tokyo
• Assistant Professor MORI Yutaro, M.D., Ph.D., Department of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
• Assistant Professor Hiroki Takeuchi, Ph.D., Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine

History

May 2019

Company established

July 2019

Capital increase through third-party allotment

August 2019

Laboratory opened

December 2019

Capital increase through third-party allotment

January 2020

In-house research ethics review committee established

May 2020

Collaboration with The Institute of Medical Science, The University of Tokyo and Juntendo University initiated

April 2021

Head office and laboratory relocated to Inspired.Lab, 6th Floor, Otemachi Building, Chiyoda-ku, Tokyo
Capital increase through third-party allotment

June 2021

Board of Directors and Audit & Supervisory Board established

April 2022

Capital increase through third-party allotment

July 2023

Raised 325 million yen from KII, Coral Capital, and one other venture capital firm through the issuance of stock acquisition rights

December 2023

Entered into a joint development agreement with Kyoritsu Seiyaku and Kyoritsu Holdings for EV formulations to treat pet diseases

February 2024

Received positive feedback from the U.S. FDA regarding the Pre-IND application for EXP01

March 2024

Raised 550 million yen from two business companies through the issuance of stock acquisition rights

July 2024

Initiated joint research with Tokyo Medical and Dental University, which has been renamed as Institute of Science Tokyo, on the development of EV therapies for kidney diseases

December 2024

Selected for the NEDO Deep Tech Startup Support Program

December 2024

Received an additional investment of 180 million JPY from Coral Capital

April 2025

Began joint research with Mie University on oocyte maturation technology for in vitro fertilization (IVF)